Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 99 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Primary Open-angle Glaucoma and Ocular Hypertension Clear all
Completed Phase 1Phase 2 Interventional

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01123785
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
INO-8875, Placebo
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 77 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Sep 30, 2026, 7:42 PM EDT
Active, not recruiting Not applicable Interventional

Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.

NCT05024695
View directory record Official record
Conditions
Glaucoma
Interventions
MINIject™ Implant
Device
Lead sponsor
iSTAR Medical
Industry
Eligibility
46 Years and older
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
28
States / cities
Glendale, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Sep 30, 2026, 7:42 PM EDT
Terminated Phase 1 Interventional

Safety Study of Latanoprost Slow Release Insert

NCT01180062
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
Latanoprost, Arm 2, Latanoprost SR insert
Drug
Lead sponsor
Daniel Moore
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Sep 30, 2026, 7:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

How Does Your Genetic Make-up (Profile) Influence Your Glaucoma?

NCT00626847
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
40 Years and older
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 30, 2026, 7:42 PM EDT
Terminated Phase 4 Interventional

A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma

NCT06407973
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
OMNI Surgical System, Latanoprost plus adjunctive glaucoma medication
Device · Drug
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
45 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Petaluma, California • Maryville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension

NCT01915940
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost, Timolol 0.5%, Placebo Eye Drops, Placebo Ocular Insert
Drug · Device
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Artesia, California • La Jolla, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Sep 30, 2026, 7:42 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults

NCT04396002
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Life Space Questionnaire, Low Luminance Questionnaire, Contrast sensitivity under dim illumination, Visual field under dim illumination (MAIA), Macular Pigment Optical Density (MPOD), Dark Adaptation
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Sep 30, 2026, 7:42 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

African Descent and Glaucoma Evaluation Study

NCT00221923
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
1,540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2022
U.S. locations
3
States / cities
Birmingham, Alabama • La Jolla, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Sep 30, 2026, 7:42 PM EDT
Completed No phase listed Observational

Results of Ocular Compression and Suture Release in Trabeculectomy and Combined Surgery

NCT00327405
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2006 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

NCT05451329
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Sep 30, 2026, 7:42 PM EDT
Terminated Not applicable Interventional Results available

Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle Glaucoma

NCT02928289
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
VISCO360 ab interno canaloplasty surgery, Selective Laser Trabeculoplasty (SLT)
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Fayetteville, Arkansas • Orange, California • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG

NCT02829996
View directory record Official record
Conditions
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
trabodenoson 6.0% / latanoprost 0.005% QD, trabodenoson 3.0% / latanoprost 0.005% QD, trabodenoson 6.0% / latanoprost 0.0025% QD, latanoprost 0.005% QD, latanoprost 0.0025% QD
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Sep 30, 2026, 7:42 PM EDT
Not listed Phase 1Phase 2 Interventional

Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension

NCT01520116
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
Stage 1 - ATS907 - Dose 1, Stage 1 - ATS907 - Dose 2, Stage 1 - ATS907 - Dose 3, Stage 1 - ATS907 - Dose 4, Stage 1 - Vehicle, Stage 2 - ATS907 - Dose A - to be selected based on Stage 1, Stage 2 - ATS907 - Dose B - to be selected based on Stage 1, Timoptic
Drug
Lead sponsor
Altheos, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
5
States / cities
Artesia, California • Glendale, California • Saint Joseph, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 1 Interventional

NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement

NCT01408472
View directory record Official record
Conditions
Glaucoma, Primary Open Angle
Interventions
NT-501 CNTF Implant
Drug
Lead sponsor
Jeffrey L Goldberg
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT05913232
View directory record Official record
Conditions
Glaucoma Open-Angle Primary, Ocular Hypertension
Interventions
H-1337 0.6%, H-1337 1.0%, H-1337 Placebo, Timolol 0.5%
Drug
Lead sponsor
D. Western Therapeutics Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Glendale, California • Colorado Springs, Colorado • Lakeland, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 30, 2026, 7:42 PM EDT
Active, not recruiting Phase 2 Interventional

Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension

NCT06964191
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic Solution
Combination Product · Drug
Lead sponsor
PolyActiva Pty Ltd
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 4 Interventional

Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs

NCT00675207
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
Brimonidine purite 0.15%, Dorzolamide 2%, Brinzolamide 1%
Drug
Lead sponsor
Northwestern Ophthalmic Institute S.C.
Other
Eligibility
41 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2008 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 2 Interventional

Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

NCT02136940
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Eye Disease
Interventions
AMA0076, Placebo
Drug
Lead sponsor
Amakem, NV
Industry
Eligibility
30 Years to 85 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Artesia, California • Inglewood, California • Petaluma, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Sep 30, 2026, 7:42 PM EDT
Terminated Not applicable Interventional

Safety and Effectiveness of the Hydrus Microstent

NCT05198297
View directory record Official record
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
Interventions
Hydrus Microstent, Ophthalmic surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Bentonville, Arkansas • Zephyrhills, Florida • Fraser, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Not applicable Interventional Results available

Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves

NCT01883856
View directory record Official record
Conditions
Glaucoma
Interventions
Silicone plate Ahmed Glaucoma Valve (Model FP7), Porous Plate Ahmed Glaucoma Valve (Model M4)
Device
Lead sponsor
Peter Netland, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 3 Interventional Results available

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

NCT04024072
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Brinzolamide 1% ophthalmic suspension, Azopt 1% Ophthalmic Suspension
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

H-1337 Ophthalmic Solution Phase 1/2

NCT03452033
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
H-1337 Placebo, H-1337 [1], H-1337 [2], H-1337 [3]
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years to 99 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Goose Creek, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Not applicable Interventional

Safety and Feasibility of the ELIOS System in POAG Patients

NCT05999006
View directory record Official record
Conditions
Glaucoma, Primary Open Angle
Interventions
ELIOS Procedure
Device
Lead sponsor
Elios Vision, Inc.
Industry
Eligibility
45 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Glendale, Arizona • Rock Island, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 4 Interventional

Dose, Effects and Characteristics of Pilocarpine

NCT00803803
View directory record Official record
Conditions
Open-angle Glaucoma
Interventions
Pilocarpine Concentration, Pilocarpine Frequency
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1978 – 1979
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 30, 2026, 7:42 PM EDT